Figure 2.
Treatment response among HER2 mutated lung cancer patients as a whole. Treatment response was different between HER2‐targeted TKIs and chemotherapy, both in (a) first‐line and (b) second‐line settings.
Treatment response among HER2 mutated lung cancer patients as a whole. Treatment response was different between HER2‐targeted TKIs and chemotherapy, both in (a) first‐line and (b) second‐line settings.